ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2021
PHASE I CLINICAL STUDY OF A NEW RADIOPHARMACEUTICAL BASED ON RECOMBINANT TARGET MOLECULES DARPIN9_29 LABELED WITH 99mTECHNETIUM FOR RADIONUCLIDE DIAGNOSIS OF THE Her2/neu-POSITIVE BREAST CANCER
Introduction. The main attention of researchers is paid to the study of one of the members of the EGF family – the receptor of epidermal growth factor 2 (Her2/neu), the overexpression of which is detected in 15–20% of cases of invasive breast cancer and had an…